Capricor Therapeutics Announces The Appointment Of Michael Binks, M.D. As The New Chief Medical Officer

Capricor Therapeutics, a biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases, has announced the appointment of Dr. Michael Binks as its new Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of extensive experience in leading global clinical development and translational research within the pharmaceutical and biotechnology industries.

Dr. Binks is a board-certified rheumatologist (UK) and a recognized expert in immunology and rare diseases. He has held senior leadership positions at Pfizer and GlaxoSmithKline, where he played a pivotal role in the advancement of several first-in-class therapies, including Benlysta, Hympavzi, Paxlovid, and Beqvez, along with numerous gene therapy, small molecule, and biologic programs through both early and late-stage development. Most recently, Dr. Binks served as Vice President and Head of Rare Disease Clinical and Translational Research at Pfizer, based in Cambridge, MA, where he led global clinical efforts across more than a dozen studies, including several in Duchenne muscular dystrophy (DMD).

Linda Marbán, Ph.D., Chief Executive Officer of Capricor, mentioned, “Michael is an outstanding addition to Capricor’s leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities. With over a decade of leadership in the DMD space, Dr. Binks is uniquely positioned to guide the medical and commercial advancement of our deramiocel program and help shape the next phase of our pipeline. This is a pivotal time to strengthen our medical leadership, and we are excited about the expertise and strategic vision he brings to the organization.”

His therapeutic expertise covers a broad range of areas, including immunology, neurology, cardiology, nephrology, and hematology. Beyond his pharmaceutical career, Dr. Binks is the founder of PathfindRx LLC, a consultancy in translational medicine, and has held academic and clinical positions at Addenbrooke’s Hospital in Cambridge and University College London. Dr. Binks earned his medical degree, postgraduate, and specialist training at University College London Medical School.